| abstract |
The use of nicotine or a pharmaceutically acceptable salt or derivative thereof together with a pharmaceutically acceptable carrier for the preparation of a medicament for the delivery of nicotine to the rectum, colon and / or terminal ileum of a patient for the treatment or prophylaxis or remission of inflammatory bowel disease. Rectally administrable postgastric delayed release pharmaceutical composition or oral pharmaceutical composition comprising nicotine or a salt thereof, or a pharmaceutically acceptable derivative together with a pharmaceutically acceptable carrier. Oral postgastric delayed release composition which is in the form of an enteric coated capsule or capsule containing enteric coated microgranules, or enteric coated capsules containing enteric coated microgranules. A pharmaceutical combination product comprising nicotine or a salt thereof, or a pharmaceutically acceptable derivative adapted for delivery to the terminal ileum or colon and a compound selected from the group consisting of 5-ASA, sulfasalazine, asalazine, prednisolone or budesonide, for simultaneous, separate or sequential administration. à |